Epilepsy with myoclonic atonic seizures: genes and variants
Explore variant evidence for Epilepsy with myoclonic atonic seizures across 1 analyzed protein (SLC6A1). Linked ClinVar records include 55 pathogenic or likely pathogenic variants, 166 variants of uncertain significance and 47 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Epilepsy with myoclonic atonic seizures
SLC6A1: Sodium- and chloride-dependent GABA transporter 1
It clears GABA from extracellular space into neurons and glial cells, regulating the duration and spatial spread of inhibitory neurotransmission. Haploinsufficiency or dysfunctional variants cause SLC6A1-related neurodevelopmental disorder, commonly with myoclonic-atonic epilepsy, developmental delay, and autism-related features.
55 ClinVar pathogenic / likely pathogenic and 213 uncertain variants in SLC6A1 have source records linked to Epilepsy with myoclonic atonic seizures. Association strength is not clinical gene validity.
Where Epilepsy with myoclonic atonic seizures variants cluster
- SLC6A1 Extracellular (positions 74–80): 5 of 53 ClinVar pathogenic / likely pathogenic variants, 8.1× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Epilepsy with myoclonic atonic seizures
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SLC6A1 A288V | 288 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 A334T | 334 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G75E | 75 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G75R | 75 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 A334P | 334 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 R44W | 44 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC6A1 A357E | 357 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G443D | 443 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 R44Q | 44 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC6A1 A357V | 357 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G111R | 111 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G307R | 307 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 V511M | 511 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G79R | 79 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G94E | 94 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 Q106R | 106 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC6A1 V125M | 125 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 F270S | 270 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G297R | 297 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G362R | 362 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC6A1 S459R | 459 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G550R | 550 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 V342M | 342 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC6A1 G75W | 75 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 A288T | 288 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 S331G | 331 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 M487V | 487 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 M487T | 487 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 V511L | 511 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 G533R | 533 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 G533D | 533 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 G124S | 124 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 R50L | 50 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 Y86H | 86 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 E101A | 101 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 S145F | 145 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 C173Y | 173 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 P247S | 247 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 L269P | 269 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 G299V | 299 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 A305V | 305 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 I338F | 338 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 L366P | 366 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 A367T | 367 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 F386S | 386 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 T400I | 400 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 L408R | 408 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC6A1 L436H | 436 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 S456R | 456 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC6A1 C499R | 499 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 P505T | 505 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 V67I | 67 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC6A1 G78C | 78 | Extracellular | Pathogenic / likely pathogenic |
| SLC6A1 Y60S | 60 | Transmembrane | Pathogenic / likely pathogenic |
| SLC6A1 L279P | 279 | Extracellular | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Epilepsy with myoclonic atonic seizures
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SLC6A1 S456C | 456 | Extracellular | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; S456R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.96 |
| SLC6A1 A305T | 305 | Transmembrane | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; A305V at the same position is pathogenic; seen in 2e-06 of gnomAD DNA copies; REVEL 0.725 |
| SLC6A1 G79E | 79 | Extracellular | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G79R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SLC6A1 R44P | 44 | Cytoplasmic | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; R44Q at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SLC6A1 G297V | 297 | Transmembrane | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G297R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SLC6A1 M487I | 487 | Cytoplasmic | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; M487V at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
Which prediction tools work for Epilepsy with myoclonic atonic seizures
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 97 out of 100
- ESM1b (LLR): 95 out of 100
- REVEL: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 93 out of 100
- CATVariant: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 89 out of 100
- PolyPhen-2: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 72 out of 100
- SpliceAI: 64 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 35 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Epilepsy with myoclonic atonic seizures
- Epilepsy, also linked to SLC6A1
Frequently asked questions
Which genes have records linked to Epilepsy with myoclonic atonic seizures?
This view contains 1 analyzed proteins: SLC6A1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 55 pathogenic or likely pathogenic variants, 166 variants of uncertain significance and 47 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 6 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 351 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center